EA201071245A1 - Новые терапевтические подходы для лечения болезни альцгеймера и связанных нарушений посредством модулирования реакции клеток на стресс - Google Patents
Новые терапевтические подходы для лечения болезни альцгеймера и связанных нарушений посредством модулирования реакции клеток на стрессInfo
- Publication number
- EA201071245A1 EA201071245A1 EA201071245A EA201071245A EA201071245A1 EA 201071245 A1 EA201071245 A1 EA 201071245A1 EA 201071245 A EA201071245 A EA 201071245A EA 201071245 A EA201071245 A EA 201071245A EA 201071245 A1 EA201071245 A1 EA 201071245A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- disease
- treatment
- alzgeymer
- modulation
- stress response
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Изобретение относится к композициям и способам для лечения болезни Альцгеймера и связанных нарушений. Более конкретно, изобретение относится к комбинированным лекарственным средствам, модулирующим реакцию клеток на стресс, для лечения указанного заболевания.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4858508P | 2008-04-29 | 2008-04-29 | |
PCT/EP2009/055207 WO2009133142A1 (en) | 2008-04-29 | 2009-04-29 | New therapeutic approaches for treating alzheimer disease and related disorders through a modulation of cell stress response |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201071245A1 true EA201071245A1 (ru) | 2011-06-30 |
EA019571B1 EA019571B1 (ru) | 2014-04-30 |
Family
ID=40873444
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201071245A EA019571B1 (ru) | 2008-04-29 | 2009-04-29 | Применение сульфизоксазола для лечения болезни альцгеймера |
Country Status (18)
Country | Link |
---|---|
US (1) | US8552041B2 (ru) |
EP (1) | EP2282779B1 (ru) |
JP (2) | JP5615805B2 (ru) |
KR (1) | KR101611824B1 (ru) |
CN (1) | CN102065897B (ru) |
AU (1) | AU2009242127B2 (ru) |
BR (1) | BRPI0911518A2 (ru) |
CA (1) | CA2722314C (ru) |
DK (1) | DK2282779T3 (ru) |
EA (1) | EA019571B1 (ru) |
ES (1) | ES2410930T3 (ru) |
IL (1) | IL208983A0 (ru) |
MX (1) | MX2010011880A (ru) |
NZ (1) | NZ589309A (ru) |
PL (1) | PL2282779T3 (ru) |
PT (1) | PT2282779E (ru) |
WO (1) | WO2009133142A1 (ru) |
ZA (1) | ZA201008039B (ru) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
AU2009242127B2 (en) * | 2008-04-29 | 2014-03-27 | Pharnext | New therapeutic approaches for treating Alzheimer disease and related disorders through a modulation of cell stress response |
WO2009133128A1 (en) | 2008-04-29 | 2009-11-05 | Pharnext | Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate |
EP2135607A1 (en) | 2008-06-18 | 2009-12-23 | Pharnext | Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders |
PT2540297E (pt) | 2008-11-19 | 2015-08-26 | Forum Pharmaceuticals Inc | Tratamento de distúrbios cognitivos com (r)-7-cloro-n- (quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida e sais farmaceuticamente aceitáveis desta |
BRPI1014793A2 (pt) * | 2009-05-11 | 2016-04-05 | Envivo Pharmaceuticals Inc | tratamento de distúrbios de cognição com determinados receptores de ácido alfa-7-nicotínico em combinação com inibidores de acetil-colinesterase |
ES2581178T3 (es) * | 2009-07-29 | 2016-09-01 | Pharnext | Nuevas herramientas de diagnóstico para enfermedad de Alzheimer |
EP2322163A1 (en) * | 2009-11-03 | 2011-05-18 | Pharnext | New therapeutics approaches for treating alzheimer disease |
US9387206B2 (en) | 2009-11-03 | 2016-07-12 | Pharnext | Therapeutic approaches for treating Alzheimer's disease |
US9283211B1 (en) | 2009-11-11 | 2016-03-15 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
ES2746850T3 (es) | 2010-05-17 | 2020-03-09 | Forum Pharmaceuticals Inc | Formulaciones farmacéuticas que comprenden formas cristalinas de clorhidrato de (R)-7-cloro-N-(quinuclidin-3-il)benzo(b)tiofeno-2-carboxamida monohidratado |
US9320793B2 (en) * | 2010-07-14 | 2016-04-26 | Acumen Pharmaceuticals, Inc. | Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42 |
DE102010062810B4 (de) * | 2010-09-07 | 2014-03-13 | Immungenetics Ag | 2-(R2-Thio)-10-[3-(4-R1-piperazin-1-yl)propyl]-10H-phenothiazine zur Behandlung neurodegenerativer Erkrankungen ausgewählt aus beta-Amyloidopathien und alpha-Synucleinopathien |
WO2012048721A1 (en) | 2010-10-14 | 2012-04-19 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases |
US8404680B2 (en) * | 2011-02-08 | 2013-03-26 | Hoffmann-La Roche Inc. | N-[3-(5-amino-3,3a,7,7a-tetrahydro-1H-2,4-dioxa-6-aza-inden-7-yl)-phenyl]-amides as BACE1 and/or BACE2 inhibitors |
US10010515B2 (en) | 2011-03-01 | 2018-07-03 | Pharnext | Therapeutic approaches for treating Parkinson's disease |
US9241933B2 (en) | 2011-03-01 | 2016-01-26 | Pharnext | Compositions for treating amyotrophic lateral sclerosis |
US9248111B2 (en) * | 2011-03-01 | 2016-02-02 | Pharnext | Therapeutic approaches for treating parkinson's disease |
EP2705842A1 (en) * | 2012-09-05 | 2014-03-12 | Pharnext | Therapeutic approaches for treating parkinson's disease |
PL2560631T3 (pl) | 2011-03-01 | 2014-06-30 | Pharnext | Terapia zaburzeń neurologicznych oparta na baklofenie i akamprozacie |
UA113165C2 (xx) * | 2011-03-01 | 2016-12-26 | Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат | |
US9867837B2 (en) | 2011-03-01 | 2018-01-16 | Pharnext | Compositions for treating neurological disorders |
US9931326B2 (en) | 2011-03-29 | 2018-04-03 | Pharnext | Composition comprising torasemide and baclofen for treating neurological disorders |
US8701980B2 (en) | 2011-10-27 | 2014-04-22 | Veltek Associates, Inc. | Air sample tracking system and method |
CA2854779A1 (en) * | 2011-11-10 | 2013-05-16 | Genentech, Inc. | Methods for treating, diagnosing and monitoring alzheimer's disease |
WO2013091670A1 (en) | 2011-12-21 | 2013-06-27 | Xigen S.A. | Novel jnk inhibitor molecules for treatment of various diseases |
AU2013224959B2 (en) * | 2012-03-01 | 2017-12-07 | Pharnext | New compositions for treating amyotrophic lateral sclerosis |
SI2819664T1 (sl) * | 2012-03-01 | 2017-12-29 | Pharnext | Novi sestavki za zdravljenje amiotrofične lateralne skleroze |
RU2635522C2 (ru) | 2012-05-08 | 2017-11-13 | Форум Фармасьютикалз, Инк. | Способы поддержания, лечения или улучшения когнитивной функции |
US10634688B2 (en) | 2013-03-06 | 2020-04-28 | Macquarie University | Assay and method for identifying compounds that reduce SIL1 expression or activity |
US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
CN105209030B (zh) * | 2013-03-15 | 2018-06-12 | 罗莎琳德富兰克林医科大学 | 用于稳定兰尼碱受体使其免于异常水平的钙释放的化合物 |
US9725429B2 (en) | 2013-03-15 | 2017-08-08 | Rosalind Franklin University Of Medicine And Science | Furanyl-imine and thiofuranyl-imine compounds for stabilizing ryanodine receptors from aberrant levels of calcium release |
WO2015197097A1 (en) | 2014-06-26 | 2015-12-30 | Xigen Inflammation Ltd. | New use for jnk inhibitor molecules for treatment of various diseases |
AU2014301631A1 (en) | 2013-06-26 | 2015-08-27 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases |
WO2014206427A1 (en) | 2013-06-26 | 2014-12-31 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
US9700544B2 (en) | 2013-12-31 | 2017-07-11 | Neal K Vail | Oral rapamycin nanoparticle preparations |
US10905672B2 (en) | 2014-02-11 | 2021-02-02 | Pharnext | Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders |
JP2018527016A (ja) * | 2015-06-24 | 2018-09-20 | オックスフォード バイオダイナミックス リミテッド | 染色体相互作用の検出 |
EP3313428A1 (en) * | 2015-06-26 | 2018-05-02 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of mild cognitive impairment |
EP3439491A1 (en) | 2015-12-13 | 2019-02-13 | Verburgh, Kris | Methods and compositions to slow down aging in cells and organisms |
KR20170113459A (ko) * | 2016-03-31 | 2017-10-12 | 한미약품 주식회사 | 타다라필 및 암로디핀 함유 고형 복합제제 |
CA3061243C (en) | 2017-04-24 | 2023-02-21 | Pharnext | Idalopirdine-based combinatorial therapies of alzheimer's disease |
JP7457505B2 (ja) * | 2017-05-10 | 2024-03-28 | ユニバーシティー オブ ロチェスター | 神経精神障害を処置する方法 |
KR20200014476A (ko) * | 2018-08-01 | 2020-02-11 | 경북대학교 산학협력단 | 설폰아마이드 유도체를 유효성분으로 함유하는 암질환 예방 또는 치료용 조성물 |
WO2020150423A1 (en) * | 2019-01-16 | 2020-07-23 | Yumanity Therapeutics, Inc. | Methods for the treatment of neurological disorders |
KR102288613B1 (ko) * | 2019-12-05 | 2021-08-11 | 대한민국 | Atg5를 이용한 경도인지장애 또는 치매의 진단 방법 |
CN115835862A (zh) * | 2020-07-10 | 2023-03-21 | 广州新创忆药物临床研究有限公司 | 治疗阿尔茨海默病的组合及其应用 |
CN113332267A (zh) * | 2021-03-31 | 2021-09-03 | 中山大学孙逸仙纪念医院 | 苯丁酸钠在制备预防或治疗帕金森病的药物中的应用 |
WO2023019351A1 (en) * | 2021-08-16 | 2023-02-23 | University Health Network | Methods and compositions for treating alpha-synuclein-mediated neurodegeneration |
CN114736959B (zh) * | 2022-05-09 | 2023-09-22 | 上海市精神卫生中心(上海市心理咨询培训中心) | 轻度认知功能损害诊断标志物、试剂盒及其应用 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4919915A (en) * | 1987-03-03 | 1990-04-24 | Paul Averback | Method for detecting the ability to prevent red-to-green congophilic birefringence |
US5231170A (en) * | 1986-08-27 | 1993-07-27 | Paul Averback | Antibodies to dense microspheres |
EP1006108A1 (en) * | 1998-12-01 | 2000-06-07 | Cerebrus Pharmaceuticals Limited | 3-Hydroxy-2(1H)-pyridinone or 3-hydroxy-4(1H)-pyridinone derivatives useful as reactive oxygen species (ROS) scavengers |
EP1006112A1 (en) * | 1998-12-01 | 2000-06-07 | Cerebrus Pharmaceuticals Limited | 3-Hydroxy-2(1H)-pyridinone or 3-hydroxy-4(1H)-pyridinone derivatives useful as reactive oxygen species (ROS) scavengers |
CN1217920C (zh) * | 2000-06-30 | 2005-09-07 | 艾兰制药公司 | 治疗早老性痴呆的化合物 |
US20030114394A1 (en) * | 2001-10-29 | 2003-06-19 | Levine Howard L. | Vaginally administered anti-dysrhythmic agents for treating pelvic pain |
PL371319A1 (en) * | 2002-01-11 | 2005-06-13 | Takeda Pharmaceutical Company Limited | Coumarin derivatives, process for their production and use thereof |
AUPS017702A0 (en) * | 2002-01-25 | 2002-02-14 | Atopic Pty Ltd | Methods and compositions for the treatment of asthma and related disorders |
US7244843B2 (en) * | 2003-10-07 | 2007-07-17 | Bristol-Myers Squibb Company | Modulators of serotonin receptors |
EP1740183B8 (en) * | 2004-03-05 | 2009-11-25 | Nycomed GmbH | Novel use for pde5 inhibitors |
JP2008504359A (ja) | 2004-07-02 | 2008-02-14 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | 病理的感染症を治療するための組成物及び方法 |
BRPI0513286A (pt) * | 2004-07-15 | 2008-05-06 | Japan Tobacco Inc | compostos de benzamida condensada e inibidores de atividade de receptor vanilóide subtipo (vr1), suas composições farmacêuticas, pacote comercial, fármaco e respectivos usos |
DE102005032625A1 (de) * | 2005-07-13 | 2007-01-25 | Saiger, Lothar, Dr. | Arzneimittel zur Behandlung neuronaler und/oder neurodegenerativer Erkrankungen |
JP2007261962A (ja) * | 2006-03-27 | 2007-10-11 | Oita Univ | 肺高血圧症に有用なエンドセリン受容体拮抗薬。 |
CN1879604A (zh) * | 2006-05-17 | 2006-12-20 | 济南帅华医药科技有限公司 | 一种含抗生素的缓释注射剂及其应用 |
JP5513113B2 (ja) * | 2006-08-31 | 2014-06-04 | アプタリス ファーマテック,インコーポレイテッド | 弱塩基性薬剤の固溶体を含む薬剤送達システム |
WO2008039514A1 (en) * | 2006-09-26 | 2008-04-03 | Cytrx Corporation | Pharmaceutical compositions and methods for treating diseases associated with neurodegeneration |
AU2009242127B2 (en) * | 2008-04-29 | 2014-03-27 | Pharnext | New therapeutic approaches for treating Alzheimer disease and related disorders through a modulation of cell stress response |
-
2009
- 2009-04-29 AU AU2009242127A patent/AU2009242127B2/en not_active Ceased
- 2009-04-29 JP JP2011506708A patent/JP5615805B2/ja not_active Expired - Fee Related
- 2009-04-29 PT PT97381867T patent/PT2282779E/pt unknown
- 2009-04-29 WO PCT/EP2009/055207 patent/WO2009133142A1/en active Application Filing
- 2009-04-29 ES ES09738186T patent/ES2410930T3/es active Active
- 2009-04-29 CN CN2009801227058A patent/CN102065897B/zh not_active Expired - Fee Related
- 2009-04-29 EA EA201071245A patent/EA019571B1/ru not_active IP Right Cessation
- 2009-04-29 PL PL09738186T patent/PL2282779T3/pl unknown
- 2009-04-29 DK DK09738186.7T patent/DK2282779T3/da active
- 2009-04-29 BR BRPI0911518A patent/BRPI0911518A2/pt not_active IP Right Cessation
- 2009-04-29 NZ NZ589309A patent/NZ589309A/en not_active IP Right Cessation
- 2009-04-29 CA CA2722314A patent/CA2722314C/en not_active Expired - Fee Related
- 2009-04-29 EP EP09738186A patent/EP2282779B1/en not_active Not-in-force
- 2009-04-29 KR KR1020107026067A patent/KR101611824B1/ko not_active IP Right Cessation
- 2009-04-29 MX MX2010011880A patent/MX2010011880A/es active IP Right Grant
-
2010
- 2010-10-28 IL IL208983A patent/IL208983A0/en not_active IP Right Cessation
- 2010-10-29 US US12/915,689 patent/US8552041B2/en not_active Expired - Fee Related
- 2010-11-10 ZA ZA2010/08039A patent/ZA201008039B/en unknown
-
2014
- 2014-06-17 JP JP2014124696A patent/JP2014205696A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2009242127B2 (en) | 2014-03-27 |
AU2009242127A1 (en) | 2009-11-05 |
ZA201008039B (en) | 2011-08-31 |
KR101611824B1 (ko) | 2016-04-12 |
EP2282779B1 (en) | 2013-03-13 |
NZ589309A (en) | 2012-03-30 |
PL2282779T3 (pl) | 2013-08-30 |
CN102065897B (zh) | 2013-11-13 |
JP2014205696A (ja) | 2014-10-30 |
PT2282779E (pt) | 2013-05-28 |
US20120071483A1 (en) | 2012-03-22 |
CA2722314C (en) | 2018-01-02 |
US8552041B2 (en) | 2013-10-08 |
WO2009133142A1 (en) | 2009-11-05 |
BRPI0911518A2 (pt) | 2017-06-13 |
DK2282779T3 (da) | 2013-05-27 |
MX2010011880A (es) | 2011-05-25 |
ES2410930T3 (es) | 2013-07-03 |
JP5615805B2 (ja) | 2014-10-29 |
KR20110011628A (ko) | 2011-02-08 |
CA2722314A1 (en) | 2009-11-05 |
CN102065897A (zh) | 2011-05-18 |
JP2011518865A (ja) | 2011-06-30 |
IL208983A0 (en) | 2011-01-31 |
EA019571B1 (ru) | 2014-04-30 |
EP2282779A1 (en) | 2011-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201071245A1 (ru) | Новые терапевтические подходы для лечения болезни альцгеймера и связанных нарушений посредством модулирования реакции клеток на стресс | |
EA201071243A1 (ru) | Комбинированные композиции для лечения болезни альцгеймера и родственных заболеваний зонизамидом и акампросатом | |
EA201200686A1 (ru) | Новые терапевтические подходы для лечения болезни альцгеймера | |
EA200901166A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr 119 | |
EA200901032A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
EA201000016A1 (ru) | Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями | |
EA201791669A3 (ru) | Новые терапевтические подходы в лечении смт и связанных с ней расстройств | |
EA201300471A1 (ru) | Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3 | |
EA201170349A1 (ru) | Модуляторы mif | |
EA201290323A1 (ru) | Селективные модуляторы рецептора сфингозин-1-фосфата и способы хирального синтеза | |
DOP2007000015A (es) | Usos terapéuticos de inhibidores de rtp801 | |
EA201001329A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
EA201590353A1 (ru) | Способы лечения болезни альцгеймера и фармацевтические композиции | |
TN2010000122A1 (en) | Compounds and compositions as modulators of gpr119 activity | |
EA201000603A1 (ru) | ПРИМЕНЕНИЕ АНТИТЕЛ К TrkB ДЛЯ ЛЕЧЕНИЯ РЕСПИРАТОРНЫХ НАРУШЕНИЙ | |
EA201100138A1 (ru) | 4-феноксиметилпиперидины в качестве модуляторов активности gpr119 | |
EA201290209A1 (ru) | Новые модуляторы бензопиран киназы | |
EA201590655A1 (ru) | Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений | |
EA201100062A1 (ru) | Соединения и способы модулирования рецепторов, связанных с белком g | |
HK1154587A1 (en) | Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators | |
EA201001332A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
EA201101686A1 (ru) | Новые композиции для лечения шмт и связанных с ней расстройств | |
MY149855A (en) | Benzimidazole derivatives and their use for modulating the gaba? receptor complex | |
EA201200570A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
EA201400969A1 (ru) | Новые терапевтические подходы для лечения болезни паркинсона |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM |
|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): RU |